KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - OtherReceivables RefundsShares Repurchased
Ratios

Sarepta Therapeutics (SRPT) EBIAT (2016 - 2025)

Sarepta Therapeutics has reported EBIAT over the past 15 years, most recently at -$412.2 million for Q4 2025.

  • Quarterly results put EBIAT at -$412.2 million for Q4 2025, down 359.18% from a year ago — trailing twelve months through Dec 2025 was -$713.4 million (down 403.27% YoY), and the annual figure for FY2025 was -$713.4 million, down 403.27%.
  • EBIAT for Q4 2025 was -$412.2 million at Sarepta Therapeutics, down from -$50.6 million in the prior quarter.
  • Over the last five years, EBIAT for SRPT hit a ceiling of $196.9 million in Q2 2025 and a floor of -$516.8 million in Q1 2023.
  • Median EBIAT over the past 5 years was -$66.0 million (2021), compared with a mean of -$106.8 million.
  • Peak annual rise in EBIAT hit 2947.86% in 2025, while the deepest fall reached 1338.98% in 2025.
  • Sarepta Therapeutics' EBIAT stood at -$122.0 million in 2021, then rose by 10.44% to -$109.2 million in 2022, then soared by 141.79% to $45.7 million in 2023, then skyrocketed by 248.37% to $159.0 million in 2024, then crashed by 359.18% to -$412.2 million in 2025.
  • The last three reported values for EBIAT were -$412.2 million (Q4 2025), -$50.6 million (Q3 2025), and $196.9 million (Q2 2025) per Business Quant data.